The risk of bone fracture resulting from falls increases as we age due to bone loss and osteoporosis. Physicians have routinely prescribed vitamin D and vitamin Drelated drugs to retard bone loss, but until now, little was known about the specific targets of vitamin D in bone. In a study appearing online on January 19 in advance of print publication in the February 2006 issue of the Journal of Clinical Investigation, Kyoji Ikeda and colleagues from the National Center for Geriatrics and Gerontology in Japan examine mice with severe osteoporosis and show that oral vitamin D treatment inhibits the production of the protein c-Fos. As c-Fos plays a key role in the development of osteoclasts, which are the specialized cells responsible for bone breakdown and resorption, the authors also show that the vitamin Dmediated inhibition of c-Fos prevented bone loss through a suppression of osteoclast development. In addition, the authors used mice whose ovaries had been removed, in a more "human-like" model of osteoporosis, to screen for other vitamin Dlike agents with c-Fossuppressing activity. They identified a new vitamin Drelated compound (DD281) that could prevent bone loss in these mice more potently than the natural vitamin D. These findings clarify how vitamin D helps limit bone resorption in conditions such as osteoporosis, and suggest that synthetic vitamin D analogs, including DD281, may warrant clinical trial to asses their potential in the treatment of osteoporosis and other related disorders of bone resorption.

TITLE: c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs

AUTHOR CONTACT:
Kyoji Ikeda
National Center for Geriatrics and Gerontology, Obu, Japan
Phone: 81-562-46-8094; Fax: 81-562-46-8094; E-mail: kikeda@nils.go.jp

View the P
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
19-Jan-2006